Solengepras

Ambroxol, a repurposed cough suppressant, shows potential as a disease-modifying therapy for Parkinson's by enhancing lysosomal function and clearing α-synuclein aggregates, with the GREAT trial currently evaluating its efficacy.

Cerevance's novel KCNK13 inhibitor CVN293 demonstrated favorable tolerability and robust brain penetration in a Phase 1 trial with 72 healthy volunteers, supporting its potential as a disease-modifying treatment for neuroinflammation-driven neurodegenerative diseases.

Cerevance's GPR6 antagonist solengepras failed to meet its primary endpoint in the Phase II ASCEND trial as a monotherapy for early, untreated Parkinson's disease patients, showing only a small, non-significant improvement versus placebo.

Cerevance has augmented its Series B-1 funding with an additional $47 million to propel its clinical pipeline of central nervous system (CNS) therapies.

Cerevance's solengepras (CVN424) has entered a Phase 3 trial (ARISE) as an adjunctive therapy for Parkinson's disease, with topline data expected in the first half of 2026.